Human(11126) Summary: CD160 is an 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine-rich, glycosylphosphatidylinositol-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. CD160 is expressed at the cell surface as a tightly disulfide-linked multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells, spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16+ cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab+CD8brightCD95+CD56+CD28-CD27-cells. In tissues, CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules. [provided by RefSeq, Jul 2008]
Save up to 60% per TRCN when you buy a set with the same options.
MISSION® siRNAs have been designed using a world-class siRNA design algorithm licensed from Rosetta Inpharmatics, a leader in advanced siRNA research. The Rosetta-powered siRNA design algorithm has been optimized with over 3 years of continuous development for enhanced performance in RNAi applications. New and critical siRNA design rules incorporated into the latest algorithm lead to increased target specificity and knockdown for low abundance messages.
Validated MISSION® siRNAs have been functionally validated in Hela cells by Sigma scientists to Knockdown gene expression by 75% or greater. With Validated MISSION® siRNAs, we have done the upfront validation work, so that you do not have to.